Skip to Main Content

Hundreds of millions of dollars have flowed to Boston-area companies investigating how to manipulate the microbiome within everyone to treat a plethora of illnesses, from serious gastrointestinal infections to food allergies to cancer.

The latest addition to that figure is $27 million to Vedanta Biosciences, which announced its Series C round on Dec. 24. The company has raised $82 million since it launched in 2010, making it one of the best-funded private companies working on microbiome therapeutics in the area. It also announced a partnership with Bristol-Myers Squibb in December.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED